Therefore, the inhibitory effect of recombinant gp130 on the promotion of IL-6 on osteoclast differentiation at low RANKL level may provide an effective therapeutic approach for the treatment of inflammatory and metabolic osteolytic diseases such as RA and postmenopausal osteoporosis. Here, TNFSF11 is linked to rheumatoid arthritis.